Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss showdown: GLP-1 drugs vs. surgery for pelvic floor health

NCT ID NCT07175805

Knowledge-focused Sponsor: Hartford HealthCare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 200 women who are either taking GLP-1 weight loss drugs or undergoing bariatric surgery. Researchers want to see how these treatments change pelvic floor symptoms like incontinence and prolapse. Participants do not need to have any pelvic floor symptoms to join. The goal is to help doctors recommend the best weight loss option for women with these issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (e.g., semaglutide) or bariatric surgery
What this could lead to
If successful, this could help doctors choose the best weight loss treatment for women with pelvic floor issues.
What could go wrong
This is an observational study, not a treatment trial. It will only measure symptoms, not prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients seeking medical weight loss or surgical weight loss at the weight loss clinics at Hartford Hospital.

Ages

18 to 90 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female * 18-89 years old * any race/ethnicity * BMI ≥30 kg/m2 * current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \& Bariatric Surgery * able/willing to give informed consent * have a home scale to measure weight Patients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm: * prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1/gastric inhibitory peptide (GIP1) * taking other weight loss agents (such as metformin) Patients meeting all the following criteria will be eligible to participate in the bariatric surgery arm: * plan to undergo gastric sleeve or gastric bypass surgery * taking weight loss agents which are not GLP-1 RA or GLP-1/GIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1/GIP1 medications after surgery. Exclusion Criteria: * Pregnant * ≥90 years old * \<18 years old * BMI \<30 kg/m2 * A history of bariatric surgery prior to enrollment * No home scale to measure weight * Active cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bariatric surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fecal Incontinence female stress incontinence Lower Urinary Tract Symptoms overactive bladder pelvic organ prolapse Urinary Incontinence, Stress Urinary Incontinence, Urge Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bariatric surgery Fecal incontinence GLP1 agonist Lower urinary tract symptoms Overactive bladder Pelvic organ prolapse Stress urinary incontinence Urge urinary incontinence Weight loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hartford Hospital

    Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.